Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database.

被引：1

作者：

Koopman, Miriam

Shi, Qian

Goey, Kaitlyn K. H.

Green, Erin

Heinemann, Volker

Diaz-Rubio, Eduardo

Aranda, Enrique

Falcone, Alfredo

De Gramont, Aimery

Sargent, Daniel J.

Punt, Cornelis J. A.

机构：

[1] Univ Med Ctr Utrecht, Utrecht, Netherlands

[2] Mayo Clin, Rochester, MN USA

[3] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany

[4] Univ Munich, Klinikum Grosshadern, Ctr Comprehens Canc, D-80539 Munich, Germany

[5] Hosp Clin San Carlos, Madrid, Spain

[6] Univ Cordoba, Maimonides Inst Biomed Res, Spanish Canc Network, Reina Sofia Hosp,Inst Salud Carlos 3, Cordoba, Spain

[7] Univ Hosp Pisa, Oncol Unit 2, Pisa, Italy

[8] Franco British Inst, Levallois Perret, France

[9] Univ Amsterdam, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.658

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

658

引用

下载

页数：1

共 50 条

[41] Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis
Yen-Cheng Chen
Tsung-Kun Chang
Wei-Chih Su
Yung-Sung Yeh
Po-Jung Chen
Peng-Jen Huang
Po-Hsiang Yang
Hsiang-Lin Tsai
Jaw-Yuan Wang
Ching-Wen Huang
International Journal of Colorectal Disease, 39 (1)
[42] Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis
Di Civita, Mattia Alberto
Torchia, Andrea
Santini, Daniele
Marinelli, Daniele
Magro, Virginia
Cerro, Marianna
Pappalardo, Laura
Maltese, Giulia
Santamaria, Fiorenza
Zacco, Luca
Buccilli, Dorelsa
Dehghanpour, Ailin
Speranza, Iolanda
Sciarra, Alessandro
Panebianco, Valeria
Roberto, Michela
CURRENT ONCOLOGY, 2024, 31 (08) : 4713 - 4727
[43] Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database.
Franko, Jan
Shi, Qian
Meyers, Jeffrey P.
Heinemann, Volker
Falcone, Alfredo
Tebbutt, Niall C.
Maughan, Tim
Seymour, Matthew
Saltz, Leonard
Tournigand, Christophe
Diaz-Rubio, Eduardo
Sougklakos, Ioannis
Chibaudel, Benoist
Moen, Joseph
De Gramont, Aimery
Adams, Richard A.
Sargent, Daniel J.
Grothey, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[44] Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.
Salvatore, Lisa
Bria, Emilio
Sperduti, Isabella
Hinke, Axel
Hegewisch-Becker, Susanna
Aparicio, Thomas
Le Malicot, Karine
Boige, Valerie
Koeberle, Dieter
Baertschi, Daniela
Dietrich, Daniel
Tortora, Giampaolo
Arnold, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
C. S. Karapetis
H. Liu
M. J. Sorich
L. D. Pederson
E. Van Cutsem
T. Maughan
J. Y. Douillard
C. J. O’Callaghan
D. Jonker
C. Bokemeyer
A. Sobrero
C. Cremolini
B. Chibaudel
J. Zalcberg
R. Adams
M. Buyse
M. Peeters
T. Yoshino
A. de Gramont
Q. Shi
British Journal of Cancer, 2024, 130 : 1269 - 1278
[46] Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
Karapetis, C. S.
Liu, H.
Sorich, M. J.
Pederson, L. D.
Van Cutsem, E.
Maughan, T.
Douillard, J. Y.
O'Callaghan, C. J.
Jonker, D.
Bokemeyer, C.
Sobrero, A.
Cremolini, C.
Chibaudel, B.
Zalcberg, J.
Adams, R.
Buyse, M.
Peeters, M.
Yoshino, T.
de Gramont, A.
Shi, Q.
BRITISH JOURNAL OF CANCER, 2024, 130 (08) : 1269 - 1278
[47] Impact of primary tumour location (PTL) on response and resection outcomes in metastatic colorectal cancer (mCRC) patients (pts) receiving first-line panitumumab (Pmab) treatment
Geissler, M.
Peeters, M.
Price, T.
Taieb, J.
Rivera, F.
Canon, J. -L.
Koukakis, R.
Burdon, P.
Siena, S.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 164 - 164
[48] Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database.
Zalcberg, John Raymond
Shi, Qian
Ferraro, Danielle Angela
Meyers, Jeffrey P.
Saltz, Leonard
Goldberg, Richard
Van Cutsem, Eric
Hurwitz, Herbert
Fuchs, Charles
Bokemeyer, Carsten
Sargent, Daniel J.
De Gramont, Aimery
Price, Timothy Jay
Adams, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[49] Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
Fotios Loupakis
Emilio Bria
Vanja Vaccaro
Federica Cuppone
Michele Milella
Paolo Carlini
Chiara Cremolini
Lisa Salvatore
Alfredo Falcone
Paola Muti
Isabella Sperduti
Diana Giannarelli
Francesco Cognetti
Journal of Experimental & Clinical Cancer Research, 29
[50] Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
Loupakis, Fotios
Bria, Emilio
Vaccaro, Vanja
Cuppone, Federica
Milella, Michele
Carlini, Paolo
Cremolini, Chiara
Salvatore, Lisa
Falcone, Alfredo
Muti, Paola
Sperduti, Isabella
Giannarelli, Diana
Cognetti, Francesco
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2010, 29

← 1 2 3 4 5 →